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Totally implantable venous intravenous access devices (TIVADs) have an essential role in the frequent delivery of
antibiotics in cystic fibrosis (CF) patients. This study at the Royal Brompton Hospital (RBH) reports the
experience of TIVADs in patients attending the RBH adult CF unit implanted at the RBH and elsewhere over a 13-
year period. The case notes of adult CF patients who had undergone TIVAD insertion were reviewed
retrospectively. The patients were divided into those who had the insertion carried out at the RBH and those who
had the device inserted elsewhere. All devices were cared for the at the RBH.
A total of 115 devices in 74 patients were reviewed. The median duration of function of 109 devices was 1429
days (range 2–3989) or 3?9 years, with a total exposure of 91 188 days or 249?8 years. There was no significant
difference between devices inserted at the RBH and those inserted elsewhere (P=0?59). Thirty-four patients had
devices installed without complications. Forty patients had complications in 62 devices. The incidence of
complications was 34?5% at the devices inserted at RBH and 73?7% elsewhere (P50?001). Of the 115 devices,
mechanical complications occurred in 42 (36%) with a median time of diagnosis of 373 days (range 1–2554),
infectious complications occurred in 16 (14%), with a median time of diagnosis of 413 days (range 40–2556) and
symptomatic venous thrombosis occurred in four (3?5%). RBH-inserted devices had significantly fewer mechanical
complications (P50?001) compared with those inserted elsewhere. The group as a whole had fewer infectious
complications than in most other reported series. We conclude that TIVADs provide effective and long-term
intravenous access and have fewer complications if they are inserted and cared for at a centre with special expertise
in their insertion and management.
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Totally implantable venous intravenous access devices
(TIVADs) have established themselves as a secure and
ecient long-term venous access in cystic fibrosis (CF)
patients. With regular intravenous antibiotic courses
peripheral veins become dicult to access and painful for
the patient. TIVADs overcome this problem and have the
advantage of being cosmetically acceptable in a subcuta-
neous location, are relatively tamper-proof and enable
ambulatory therapy at home. Since the first report of the
use of such a device in 1986 (1) in a CF paediatric patient
there have been several reports of the use and experience of
such TIVADs. These reports have ranged in duration from
2 years with 13 patients (2) to 10 years with 44 patients (3)Received 8 June 1999 and accepted in revised form 25 July 2000.
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ranged from 4 years in 58 patients (5) to 8 years in 27
patients (6). This larger study at the Royal Brompton
Hospital (RBH) reports the experience of 115 TIVADs in
74 patients attending the RBH adult CF unit implanted at
the RBH and elsewhere over a 13-year period between July
1985 and July 1998.
Methods
The case notes of patients attending the adult CF unit at the
RBH who had undergone TIVAD insertion in the above
period were reviewed retrospectively. Individuals who had
their devices managed at other hospitals were excluded
from the study. Patients were divided into those who had
the TIVAD inserted at the RBH and those who had the
procedure done elsewhere. All devices, however, were
maintained and cared for at the RBH. Patient demographic
details, operative summaries, lung function at the time of
TIVAD insertion together with device duration and
complications until the end of November 1998 were# 2000 HARCOURT PUBLISHERS LTD
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increasing frequency of intravenous antibiotics and di-
culty in obtaining peripheral venous access. The actual
duration of function of more than half the devices is not
known due to either premature removal (death or
transplantation) or the devices still being present at the
time of this study. Therefore to summarize the data and to
compare the two groups of devices, the statistical method of
survival analysis was used. The median duration was
obtained from the survival curve. Differences between the
survival curves were tested using the likelihood ratio test,
comparing the devices inserted at the RBH with those
inserted elsewhere.
METHOD OF DEVICE INSERTION
Under general anaesthetic the left or right delto-pectoral
groove is explored, gently separating the pectoralis major
from the deltoid muscle. At the base of this groove lies the
cephalic vein which can usually be cannulated easily, and in
this way a cannula is passed indirectly into the left
subclavian vein. Using a J-shaped guide wire, and under
fluoroscopy, it is possible to determine the precise position
of the tip of the cannula in the right side of the heart. This is
important to avoid both too proximal a position in the
superior vena cava where the cannula can easily be
displaced into a jugular vein or too distal a placement
through the tricuspid valve. This is even more important in
children where the distances are smaller. After confirming
satisfactory position by X-ray, satisfactory flush and
withdrawal is confirmed and, through the same incision in
the delto-pectoral groove, a pocket is made on the anterior
chest wall where the portacath hub is positioned. This has
the advantage of allowing secure fixation of the device and
potentially less chance of device infection as the anterior
chest wall is a relatively hygienic body area. The portacath
hub is secured with sutures to the pectoralis muscle,
allowing subsequent placement of the needle through the
skin to be much easier onto a fixed target. The wound is
closed with absorbable suctures and no drains.
Results
A total of 115 TIVADs were inserted in 74 adult patients
under our care. There were 58 devices fitted in 33 patients at
the RBH (mean FEV1 1?3 and FVC 2?1 at insertion) and 57
devices fitted in 41 patients elsewhere (mean FEV1 1?2 and
mean FVC 2?0). There was no significant difference in the
FEV1 and FVC or in sex distribution of patients between
the two groups. In the ‘elsewhere’ group the first device
insertion was in 1985 and in the ‘RBH’ group the first
insertion was in 1990. Median age at first device insertion
was 21?5 years (range 9*–70 years). Of the 74 patients, 43
(58%) received just one device, 25 patients (34%) received
two devices, three (4%) patients received three devices and
three (4%) patients received four devices. The TIVAD*This patient had her original insertion done in the paediatric unit
with a subsequent replacement in the adult unit.insertions at the RBH were done under general anaesthetic
except in two instances, and those done elsewhere, except in
four instances, were done under local anaesthetic. The
general anaesthetic group had one pneumothorax and one
admission to the intensive care unit due to diculty in
extubating the patient. Both patients made a full recovery.
There were no deaths resulting from the TIVAD insertion.
The duration of function of all TIVADs ranged from
2 to 3989 days. Duration was known for 109 of the 115
TIVADs, of which 59 were still functioning at death or
transplantation or the time of this survey. The median
duration of function for all patients was 1429 days (range
2–3989 days) or 3?9 years, with a total exposure of 91 188
days or 249.8 years. The median duration was 1481 days at
the RBH and 1344 days elsewhere. There was no significant
difference in device duration between the ‘RBH’ and
‘elsewhere’ device groups (P=0?59).
A similar analysis was performed to obtain the duration
of function of the first device. Duration was known for 70
of the 74 first devices, of which 37 were still functioning at
death or transplantation or the time of this survey. The
median duration for all patients was 1115 days (range 2–
3989 days), with a total exposure of 61 298 days. The
median duration was 1481 days at the RBH and 1033 days
elsewhere. There was no significant difference between the
two groups (P=0?70).
Complications are summarized in Table 1. Of the 115
TIVADs, 62 had complications in 40 patients. Thus of the
58 RBH devices inserted 20 devices (34?5%) had complica-
tions and 42 out of the 57 devices inserted elsewhere
(73?7%) had complications (P50?001).
MECHANICAL COMPLICATIONS
The types of mechanical complications are summarized in
Table 2. Of the 115 devices 42 (36%) had mechanical
complications, 11 out of the 58 (19%) devices inserted at
the RBH and 31 out of the 57 (54?4%) inserted elsewhere
(P50?001), resulting in 25 TIVADs being removed. The
median duration of 39 devices was 373 days (range 1–2554
days). The median duration was 373 days at the RBH and
393 days elsewhere. The high incidence of catheter
occlusion in the devices implanted elsewhere was mainly
due to catheter kinking related to the implantation
procedure and in one case due to the distal catheter end
lodging against a vessel wall.
SYMPTOMATIC VENOUS THROMBOSIS
Symptomatic venous thrombosis occurred in only four
devices (3?5%) in four patients. There were three cases of
superior vena cava obstruction (SVCO) and one case of leg
thrombosis. One patient presented on day 260 after device
insertion. She was on the oral contraceptive pill at the time
and was subsequently found to have Factor V Leiden
mutation. The remaining three patients had no identified
risk factors for thrombosis. The second patient presented
on day 29 after device insertion and the third patient on day
167. The final patient whose device was in the femoral vein
TABLE 1. Summary of complications
Location of device insertion
RBH Elsewhere Total
No. of patients 33 41 74
No. of TIVADs 58 57 115
Devices with complications 20 42 62 (P50?001)
Devices with mechanical complications 11 31 42 (P50?001)
Devices with symptomatic venous thrombosis 1 3 4
Devices with infection 8 8 16
TABLE 2. Types of mechanical complications and their
frequency
Frequency of episode at different
insertion locations
Type of mechanical
complication
RBH Elsewhere Total
Catheter occlusion 5 9 14
Displaced catheter 2 8 10
Displaced port 1 3 4
Ruptured port 0 2 2
Local skin breakdown 1 7 8
Pain at port site 4 6 10
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swelling. All patients were treated with anti-coagulation
and the device was removed in three patients. None of the
four patients received thrombolysis.
INFECTIOUS COMPLICATIONS
Infectious complications occurred with 16 of the 115
devices (13?9%) in 13 patients. The median duration of
function of 15 devices was 413 days (range 40–2556). The
median duration was 393?5 days at the RBH and 598 days
in devices elsewhere-inserted. There was no significant
difference between the incidence of infection at the RBH
and elsewhere-inserted devices (P=0?56). Fifteen devices
required removal due to infection. Devices were removed if
the patient had an unexplained pyrexia or had a positive
blood culture taken through the device. The only occasion
when the device was retained was with skin infection over
the insertion site. This was treated with resting the device,
local wound care and antibiotics through a peripheral
venous line. No organism was cultured from the puncture
site. Twelve patients had systemic symptoms and signs of
sepsis. Of these, three patients grew Candida species from
both the device and peripheral blood culture. One patient
grew Pseudomonas aeruginosa from the device and periph-eral blood culture. The remaining eight patients did not
have any organisms cultured but their symptoms and signs
of infection resolved with device removal and an anti-
pseudomonal antibiotic regime. Ten of these patients were
on steroids, two patients had infective respiratory exacer-
bation, one patient was a diabetic and asplenic, and two
patients were post-lung transplantation at the time of the
infective episode. There were no deaths related to device
sepsis.
In total, 49 devices required removal due to complica-
tion. There were nine devices removed at lung transplanta-
tion and 31 devices were still in situ at the time of patient
death. There are 24 devices still in regular use at the time of
this study. Two patients with devices have been lost to
follow-up.
Discussion
There is no doubt that TIVADs are a very effective and
ecient means of intravenous access in CF patients. They
are not, however, without complications. Devices inserted
at the RBH had a significantly lower complication rate than
devices inserted elsewhere, despite the same instruction
being given for the care of the device to the patient. The
incidence of mechanical complications was significantly
lower in the RBH-inserted devices compared to devices
inserted elsewhere and within the ranges quoted in other
series (13?6–53%) (2–6). There may be two reasons for the
difference between our two sets of devices. Firstly, the
devices in the ‘elsewhere’ group had been in place for a
longer duration than the RBH devices and would thus be
expected to have more complications. Secondly, the devices
at RBH, except on three occasions, were always installed by
the same senior cardiothoracic surgeon under general
anaesthetic, except in two instances where a local anaes-
thetic was used. The anaesthetic was always given by a
consultant anaesthetist with considerable experience of CF
patients. In contrast, procedures for devices installed
elsewhere were performed by various surgeons and surgical
trainees and, except in four instances, under local anaes-
thetic. This indicates that surgical expertise may decrease
the incidence of mechanical device complications. In
addition, a general anaesthetic will allow the procedure to
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as movement and coughing and allows the surgeon to take
time with the procedure. Our early experience of perform-
ing these procedures under local anaesthetic was dicult as
the patient had to be sitting up to enable satisfactory
ventilation, and there was a small but definite risk in this
position of inducing air embolism. Occasionally, a cephalic
vein is not seen and direct cannulation of the subclavian
vein is required. In this situation, if the patient is sitting and
the procedure is being performed under local anaesthetic,
there is a very definite risk of air embolus. We therefore
prefer a general anaesthetic. General anaesthesia also
allows thorough bronchial toilet to be performed shortly
before extubation. The anaesthetic protocol at the RBH for
TIVAD insertion procedure involves transfer of the patient
post-procedure to the recovery room still intubated where
suctioning of respiratory secretions and physiotherapy is
given to the patient prior to extubation. In approximately
the last 50 cases at the RBH we have routinely used 0?5%
bupivacaine to infiltrate the wound to address the problem
of wound pain. This allows early commencement of
physiotherapy when extubated.
Mechanical ventilation increases the risk of pneumothor-
ax, but there was only one episode of pneumothorax (1?4%
of all patients) in this study and it occurred on an occasion
where a junior surgical trainee performed the insertion.
Morris et al. (5) reported an incidence of 4?4% for
pneumothoraces within 24 h of device insertion. These
insertions were done under local anaesthetic (96%) by a
surgical house ocer under supervision. In this series a
further three delayed ipsilateral pneumothoraces were
reported and were possibly related to the device insertion.
Pneumothorax is a very serious complication in CF and
every precaution must be taken to minimize the risk of this
complication (11).
Symptomatic venous thrombosis was not a common
occurrence in our study (3?5% of devices), with only four
patients affected. Sola et al. (4) reported an incidence of
symptomatic thrombosis at 13?6% of devices over a 6-year
period. This experience prompted them to give aspirin
prophylaxis to all patients who had no liver disease or
bleeding disorder. This has not been the practice at our
institution.
The incidence of infectious complications was 13?9% of
all devices. The incidence of infection in the RBH-inserted
devices did not differ form the elsewhere-inserted devices
despite the longer duration of the latter devices. Given that
all devices under the RBH are cared for in exactly the same
way there is no surprise that the incidence of infection did
not differ between the RBH and divices inserted elsewhere.
Our overall infection incidence is also low when compared
with that reported in other series (15–19%) on devices with
shorter follow-up periods (3, 5, 6), despite the fact that our
group has two patients who are immunosuppressed post-
lung transplant and thus are very high risk for sepsis. The
RBH-inserted devices developed infection over a shorter
time period compared to the devices inserted elsewhere and
this may be due to the former group having more high-risk
patients. The study by Cassey et al. (2) reported no episodes
of device infection in 13 paediatric patients over 2 years. Inthis study the authors point out the importance of sterile
nursing procedure to care for the device and they felt that
the home use of such devices was inappropriate. They
further recommended that the device reservoir and line be
kept free of blood. At the RBH, strict aseptic technique and
meticulous patient training in every aspect of TIVAD care
is undertaken. Self-administration of intravenous antibiotic
at home is common practice. The patients are trained in
aseptic technique and device management by experienced
nursing staff. A CF nurse specialist is able to visit the
patient’s home and supervise therapy if required. Depart-
mental policy is that TIVADs should not be used for blood
sampling or parenteral nutrition unless absolutely neces-
sary.
This study concludes that TIVADs provide a relatively
safe and effective long-term intravenous access in adult CF
patients and have fewer complications if they are installed
at a centre where only one surgeon with particular expertise
does the procedure and where there is nursing expertise to
train the patient to care for the device.
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